In part 4 of an interview with The American Journal of Managed Care®, Frederick L. Locke, MD, provides insight on the design ...

Curocell Inc., Daejeon, Republic of Korea.

In an interview with Targeted Oncology, Frederick Locke, MD, discussed the mechanism of action of 2 allogeneic CD19-directed CAR T-cell products and next steps for their evaluation for the treatment ...

Strategic pipeline prioritization with workforce and cost reductions expected to extend the company’s cash runway by one year into H2 2027 -- -- Two robust clinical datasets from CB-010 and CB-011 now ...

Making ‘off-the-shelf’, or allogeneic, cancer-killing immunotherapies ... cells work differently from the T-cells upon which CAR-T therapies are based – NKs are usually involved in killing ...

Crispr Therapeutics is an emerging gene editing company focused on the development of Crispr/Cas9-based therapeutics. The company's proprietary platform specializes in clustered regularly interspaced ...

Sana Biotechnology, Inc.’s SANA share price has surged by 7.80%, which has investors questioning if this is right time to sell.

EPALINGES, Switzerland and PARIS, April 22, 2025 /PRNewswire/ — Onward Therapeutics SA, a biotechnology company dedicated to advancing innovative cancer immunotherapies, announced that its subsidiary, ...

Allogene Therapeutics, Inc.’s ALLO share price has surged by 5.28%, which has investors questioning if this is right time to ...

Moreover, the quality of T-cells from autoimmune patients – already compromised by disease burden or chronic immunosuppressive therapy – can affect treatment efficacy. Allogeneic CAR-T ...